Moderate use averts failure of type 2 diabetes drugs in animal model

October 28, 2008

Drugs widely used to treat type 2 diabetes may be more likely to keep working if they are used in moderation, researchers at Washington University School of Medicine in St. Louis have found in a study using an animal model.

The drugs, sulfonylureas, help type 2 diabetics make more insulin, improving control of blood sugar levels. But in most patients the effects of sulfonylureas are lost after several years of use, causing insulin secretion to shut down. This typically forces patients to switch to regular insulin injections.

"Why this happens isn't clear yet, but we've found what may be cause for hope," says senior author Colin G. Nichols, Ph.D., the Carl F. Cori Professor and professor of cell biology and physiology. "We've shown in a mouse model that whatever causes this shutdown doesn't kill the insulin-making beta cells of the pancreas or stop them from making insulin. Instead, it somehow stops them from secreting insulin."

When they stopped receiving the drug, beta cells began secreting insulin again hours later. Nichols and co-author Maria Sara Remedi, Ph.D., instructor of cell biology and physiology, report the findings in Public Library of Science Medicine.

"I find these experimental observations very exciting," says Alan Permutt, M.D., professor of medicine and of cell biology and physiology. "But I'm very cautious that patients understand that the relevance of this model to human diabetes and its treatment still needs to be tested."

If human beta cells also survive and can continue to produce insulin after long-term sulfonylurea exposure, it may be possible to rethink treatment strategies, Nichols suggests.

"Doctors now prescribe new long-acting sulfonylureas to establish a chronic presence of the drug in the bloodstream," he says. "But it may be beneficial to use the older drugs that go away more quickly, allowing the beta cells time to recover."

Another potential option would be alternating periods of drug treatment with periods when the patient's symptoms are managed by insulin injection, Nichols suggests.

Type 2 diabetes accounts for 90 percent to 95 percent of the estimated 16 million Americans with diabetes. Patients with the disorder develop resistance to insulin, a hormone that helps the body control blood sugar levels. In many cases, their beta cells also make less insulin. Physicians typically treat the condition with a sulfonylurea and metformin, a drug that increases insulin sensitivity.

Sulfonylureas bind to potassium channels on the surfaces of beta cells. These channels normally control electrical activity and hence the levels of calcium in the cell; when the drug blocks the channels, calcium levels rise in the beta cell, causing release of insulin.

Nichols and Remedi saw an important opportunity to learn about the long-term failure of sulfonylureas with the availability of an implantable time-release capsule form of one of the drugs, glibenclamide. They implanted the capsules in the necks of mice. As expected, the drugs initially caused mouse beta cells to release more insulin and blood sugar levels dropped rapidly. Within a few days, though, the response to the drug reversed: Insulin secretion levels dropped, and blood sugar levels rose dramatically.

Examination of the pancreas showed that the animals' beta cells were still alive and contained normal levels of insulin.

"The problem seems to lie somewhere between the trigger for secreting insulin, which was hyperactivated while they were on the medication, and the actual mechanisms that release insulin," Nichols says. "The insulin is there, it's just not ready to release."

Nichols and Remedi are currently seeking further insight into the causes of this breakdown.

Washington University School of Medicine

Biophysics of the Pancreatic B-Cell (NATO Asi Series) (Vol 211)
by Illani Atwater (Author), Eduardo Rojas (Author), Bernat Soria (Author)

Pancreatic Beta Cell in Health and Disease
by Susumu Seino (Editor), Graeme I. Bell (Editor)

The beta cells of the pancreatic islets of Langerhans are the only cells in the body that produce and secrete insulin. This metabolic hormone plays a central role in the maintenance of glucose homeostasis. This book provides a comprehensive review of the beta cell in health and disease. The book’s primary aim is to encourage investigators to become actively involved in diabetes research and the search for new approaches to prevent and treat diabetes.

Islet Transplantation and Beta Cell Replacement Therapy
by A.M. James Shapiro (Editor), James A.M. Shaw (Editor)

Beta cell replacement through transplantation remains the only treatment option for Type 1 diabetes enabling restoration of near-physiological glucose levels without significant hypoglycemia. Outlining the most recent advances and research breakthroughs, this practical guide and reference work explores the impact of islet cell transplantation and brings together leading multidisciplinary proponents critical to future success in the field. Edited by a surgeon and an endocrinologist at the forefront of the technology, this volume considers challenges associated with this procedure including lack of sufficient donor organs and the side effects of immunosuppressive therapy, as well as the potential benefits for current and future patients.

Beta Cells: Functions, Pathology and Research (Cell Biology Research Progress)
by Sarah E. Gallagher (Editor)

Beta cells or ss-cells, are a type of cell in the pancreas in areas called the islets of Langerhans. They make up 65-80 percent of the cells in the islets. Pancreatic B-cell is the only cell type that produces insulin to regulate glucose metabolism in the body. The insufficiency of insulin-producing B-cells results in dysregulation of blood glucose control, termed as type 1 diabetes. This book presents current research from across the globe in the study of Beta-cells, including the induction of pancreatic cancer cell death by elevated concentrations of extracellular zinc; the role of Rab GTPases and their effectors in the insulin secretory pathway of the pancreatic beta cell; In vivo reprogramming of pancreatic A-cells into B-like cells; and the role of glucocortoids, exercise and...

Beta-cell: Webster's Timeline History, 1955 - 2007
by Icon Group International (Author)

Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Beta-cell," including when used in literature (e.g. all authors that might have Beta-cell in their name). As such, this book represents the largest compilation of timeline events associated with Beta-cell when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social sciences...

Pancreatic beta cell culture: Proceedings of the fifth workshop conference Hoechst, Kitzbuhel, 5-9 October 1976 (International congress series)
by sole distributors for the USA, Elsevier North-Holland (Publisher)

Perspectives on the Molecular Biology and Immunology of the Pancreatic B Cell (Current Communications in Cell and Molecular Biology)
by Douglas Hanahan (Author), Hugh O. McDevitt (Author), George F. Cahill (Editor)

Antibiotic Inhibitors of Bacterial Cell Wall Biosynthesis
by Donald J. Tipper (Author)

Since the advent of antibiotic drugs, epidemic bacterial infections have ceased to be a scourge on mankind. This volume presents an overview of the field of antibiotic action. It also includes descriptions of the major mechanisms of resistance that are increasingly becoming a serious problem in dealing with bacterial infections. In detailing the precise mechanisms of action and resistance, allied to the rational application of modern organic chemistry, this information should highlight better structures for classical antibiotics, as well as other areas of bacterial metabolism that may be sensitive to chemotherapy. In such a multidisciplinary field, this accumulation of knowledge should be invaluable to all those working on better antibiotics.

FCT Cuts Costs of Cells in Beta Units.(Fuel Cell Technologies): An article from: Fuel Cell Technology News
by Gale Reference Team (Author)

This digital document is an article from Fuel Cell Technology News, published by Thomson Gale on December 1, 2004. The length of the article is 590 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: FCT Cuts Costs of Cells in Beta Units.(Fuel Cell Technologies)
Author: Gale Reference Team
Publication: Fuel Cell Technology News (Newsletter)
Date: December 1, 2004
Publisher: Thomson Gale
Volume: 7 Issue: 3 Page: NA

Distributed by Thomson...

Pancreatic beta cell agenesis: An entry from Thomson Gale's Gale Encyclopedia of Genetic Disorders, 2nd ed.
by Toni, MS, CGC Pollin (Author)

Information on many genetic disorders, and the frequent new findings on them, has been extremely difficult to come by—until now. The “Gale Encyclopedia of Genetic Disorders” addresses the need for current, hard-to-find facts on emerging discoveries. The two-volume Encyclopedia, presented in a single alphabetical sequence, provides clear, complete information on genetic disorders, including conditions, tests, procedures, treatments and therapies, in articles that are both comprehensive and easy to understand, in language accessible to laypersons. The articles are arranged in a standardized format for quick comparison and ease of use, while non-disorder topics are covered in detail with extended entries. Students will want to consult the “Gale Encyclopedia of Genetic Disorders”...